Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for treating diabetes and complication thereof

A composition and diabetes technology, applied in the field of medicine, can solve the problems of undiscovered arctigenin and pioglitazone, etc., and achieve the effects of reducing the level of glycosylated serum protein, improving blood sugar, and lowering blood lipids

Active Publication Date: 2011-11-02
江苏叠石桥家纺产业集团有限公司
View PDF4 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, through the retrieval of public publications at home and abroad, it has been found that arctigenin and pioglitazone or its salts have been reported in the prior art to treat diabetes and its complications alone, but arctigenin and pioglitazone or its salts have not been found at present. Related reports on the treatment of diabetes mellitus and its complications by compound medicine

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating diabetes and complication thereof
  • Pharmaceutical composition for treating diabetes and complication thereof
  • Pharmaceutical composition for treating diabetes and complication thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Embodiment 1: Granules

[0029] formula:

[0030]

[0031] Appropriate amount of 5% polyvinylpyrrolidone aqueous solution

[0032] Preparation method: pass pioglitazone hydrochloride, arctigenin and auxiliary materials through 80-mesh sieve respectively for later use. Weigh pioglitazone hydrochloride, lactose, starch, and L-HPC according to the prescription, mix them uniformly by the method of equal increase, add 5% polyvinylpyrrolidone aqueous solution to make soft material, pass through a 24-mesh sieve to granulate, dry at 60°C, pass through 24 Mesh sieve for whole grains. The arctigenin and the microcrystalline cellulose are evenly mixed, granulated by a dry method, and granulated through a 24-mesh sieve. After the above two granules are evenly mixed with magnesium stearate and micropowder silica gel, they are directly subpackaged to make granules.

Embodiment 2

[0033] Embodiment 2: Granules

[0034] formula:

[0035]

[0036] Appropriate amount of 5% polyvinylpyrrolidone aqueous solution

[0037] Preparation method: pass pioglitazone hydrochloride, arctigenin and auxiliary materials through 80-mesh sieve respectively for later use. Weigh pioglitazone hydrochloride, lactose, starch, and L-HPC according to the prescription, mix them uniformly by the method of equal increase, add 5% polyvinylpyrrolidone aqueous solution to make soft material, pass through a 24-mesh sieve to granulate, dry at 60°C, pass through 24 Mesh sieve for whole grains. The arctigenin and the microcrystalline cellulose are evenly mixed, granulated by a dry method, and granulated through a 24-mesh sieve. After the above two granules are evenly mixed with magnesium stearate and micropowder silica gel, they are directly subpackaged to make granules.

Embodiment 3

[0038] Embodiment 3: tablet

[0039] formula:

[0040]

[0041] Preparation process: Pass the pioglitazone hydrochloride and arctigenin in the prescription through an 80-mesh sieve, microcrystalline cellulose and low-substituted hydroxypropyl cellulose through an 80-mesh sieve, and weigh the prescribed amount of pioglitazone hydrochloride, arctigenin and low-substituted hydroxypropyl cellulose. Mix propylcellulose and microcrystalline cellulose evenly, add 2% hydroxypropyl methylcellulose solution to granulate in an appropriate amount, dry at 60°C, granulate with a 16-mesh sieve, add prescription amount of magnesium stearate to the dry granules and mix evenly , ready to be pressed into tablets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition for treating diabetes and complication thereof, and particularly relates to a composition containing arctigenin and PioglitaZone or pharmaceutically acceptable salts thereof and to the purpose of the composition in preparing medicines for treating diabetes, diabetic complication and diseases related to diabetes.

Description

technical field [0001] The invention belongs to the technical field of medicine, in particular to a pharmaceutical composition for treating diabetes and its complications, in particular to a pharmaceutical composition containing arctigenin and pioglitazone or a pharmaceutically acceptable salt thereof. Background technique [0002] According to the statistics of the World Health Organization (WHO), there are currently about 194 million people with diabetes in the world, which will double by 2030. The number of diabetic patients in China has reached about 40 million, ranking second in the world after India. Type 2 diabetes accounts for about 90%-95% of the total number of diabetic patients in my country. Type 2 diabetes has become one of the major diseases threatening our national health. According to the latest epidemiological survey of diabetes in China by Diabetes Society of Chinese Medical Association, there are about 41 million people with diabetes among the urban popu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/365A61K31/4439A61P3/10A61P3/04A61P9/12A61P9/10A61P13/12A61P25/28
Inventor 刘树芹
Owner 江苏叠石桥家纺产业集团有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com